vs

Side-by-side financial comparison of Kontoor Brands, Inc. (KTB) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Kontoor Brands, Inc. is the larger business by last-quarter revenue ($853.2M vs $622.0M, roughly 1.4× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 4.3%, a 30.1% gap on every dollar of revenue. On growth, Kontoor Brands, Inc. posted the faster year-over-year revenue change (27.3% vs 4.8%). Over the past eight quarters, Kontoor Brands, Inc.'s revenue compounded faster (14.2% CAGR vs 4.6%).

Kontoor Brands is an American clothing company. It was a spin off from the VF Corporation in May 2019, and markets clothing under the Lee, Wrangler and Helly Hansen brand names.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

KTB vs RPRX — Head-to-Head

Bigger by revenue
KTB
KTB
1.4× larger
KTB
$853.2M
$622.0M
RPRX
Growing faster (revenue YoY)
KTB
KTB
+22.5% gap
KTB
27.3%
4.8%
RPRX
Higher net margin
RPRX
RPRX
30.1% more per $
RPRX
34.4%
4.3%
KTB
Faster 2-yr revenue CAGR
KTB
KTB
Annualised
KTB
14.2%
4.6%
RPRX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
KTB
KTB
RPRX
RPRX
Revenue
$853.2M
$622.0M
Net Profit
$36.9M
$214.2M
Gross Margin
41.3%
Operating Margin
7.5%
62.4%
Net Margin
4.3%
34.4%
Revenue YoY
27.3%
4.8%
Net Profit YoY
-47.6%
2.9%
EPS (diluted)
$0.66
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KTB
KTB
RPRX
RPRX
Q4 25
$622.0M
Q3 25
$853.2M
$609.3M
Q2 25
$658.3M
$578.7M
Q1 25
$622.9M
$568.2M
Q4 24
$699.3M
$593.6M
Q3 24
$670.2M
$564.7M
Q2 24
$606.9M
$537.3M
Q1 24
$631.2M
$568.0M
Net Profit
KTB
KTB
RPRX
RPRX
Q4 25
$214.2M
Q3 25
$36.9M
$288.2M
Q2 25
$73.9M
$30.2M
Q1 25
$42.9M
$238.3M
Q4 24
$64.0M
$208.2M
Q3 24
$70.5M
$544.0M
Q2 24
$51.8M
$102.0M
Q1 24
$59.5M
$4.8M
Gross Margin
KTB
KTB
RPRX
RPRX
Q4 25
Q3 25
41.3%
Q2 25
46.3%
Q1 25
47.5%
Q4 24
43.7%
Q3 24
44.7%
Q2 24
44.7%
Q1 24
45.2%
Operating Margin
KTB
KTB
RPRX
RPRX
Q4 25
62.4%
Q3 25
7.5%
70.1%
Q2 25
11.9%
36.3%
Q1 25
11.8%
94.0%
Q4 24
12.1%
60.9%
Q3 24
14.7%
Q2 24
12.4%
50.2%
Q1 24
13.4%
-13.0%
Net Margin
KTB
KTB
RPRX
RPRX
Q4 25
34.4%
Q3 25
4.3%
47.3%
Q2 25
11.2%
5.2%
Q1 25
6.9%
41.9%
Q4 24
9.1%
35.1%
Q3 24
10.5%
96.3%
Q2 24
8.5%
19.0%
Q1 24
9.4%
0.8%
EPS (diluted)
KTB
KTB
RPRX
RPRX
Q4 25
$0.49
Q3 25
$0.66
$0.67
Q2 25
$1.32
$0.07
Q1 25
$0.76
$0.55
Q4 24
$1.13
$0.46
Q3 24
$1.26
$1.21
Q2 24
$0.92
$0.23
Q1 24
$1.05
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KTB
KTB
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$82.4M
$618.7M
Total DebtLower is stronger
$1.3B
$9.0B
Stockholders' EquityBook value
$529.6M
$9.7B
Total Assets
$2.9B
$19.6B
Debt / EquityLower = less leverage
2.53×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KTB
KTB
RPRX
RPRX
Q4 25
$618.7M
Q3 25
$82.4M
$938.9M
Q2 25
$107.5M
$631.9M
Q1 25
$356.7M
$1.1B
Q4 24
$334.1M
$929.0M
Q3 24
$269.4M
$950.1M
Q2 24
$224.3M
$1.8B
Q1 24
$215.1M
$843.0M
Total Debt
KTB
KTB
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$1.3B
$8.9B
Q2 25
$1.4B
$8.0B
Q1 25
$735.6M
$7.6B
Q4 24
$740.3M
$7.6B
Q3 24
$745.0M
$7.6B
Q2 24
$749.7M
$7.6B
Q1 24
$779.2M
$6.1B
Stockholders' Equity
KTB
KTB
RPRX
RPRX
Q4 25
$9.7B
Q3 25
$529.6M
$9.6B
Q2 25
$498.3M
$9.5B
Q1 25
$426.7M
$9.8B
Q4 24
$400.1M
$10.3B
Q3 24
$356.9M
$10.3B
Q2 24
$367.2M
$9.8B
Q1 24
$387.2M
$9.9B
Total Assets
KTB
KTB
RPRX
RPRX
Q4 25
$19.6B
Q3 25
$2.9B
$19.3B
Q2 25
$2.7B
$18.3B
Q1 25
$1.7B
$17.6B
Q4 24
$1.7B
$18.2B
Q3 24
$1.7B
$18.0B
Q2 24
$1.6B
$17.7B
Q1 24
$1.7B
$16.1B
Debt / Equity
KTB
KTB
RPRX
RPRX
Q4 25
0.92×
Q3 25
2.53×
0.93×
Q2 25
2.74×
0.84×
Q1 25
1.72×
0.78×
Q4 24
1.85×
0.74×
Q3 24
2.09×
0.74×
Q2 24
2.04×
0.78×
Q1 24
2.01×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KTB
KTB
RPRX
RPRX
Operating Cash FlowLast quarter
$64.1M
$827.1M
Free Cash FlowOCF − Capex
$55.8M
FCF MarginFCF / Revenue
6.5%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
1.74×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$228.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KTB
KTB
RPRX
RPRX
Q4 25
$827.1M
Q3 25
$64.1M
$702.6M
Q2 25
$25.7M
$364.0M
Q1 25
$77.6M
$596.1M
Q4 24
$82.0M
$742.5M
Q3 24
$133.6M
$703.6M
Q2 24
$96.2M
$658.2M
Q1 24
$56.5M
$664.6M
Free Cash Flow
KTB
KTB
RPRX
RPRX
Q4 25
Q3 25
$55.8M
Q2 25
$22.4M
Q1 25
$74.9M
Q4 24
$75.0M
Q3 24
$129.9M
Q2 24
$92.6M
Q1 24
$52.0M
FCF Margin
KTB
KTB
RPRX
RPRX
Q4 25
Q3 25
6.5%
Q2 25
3.4%
Q1 25
12.0%
Q4 24
10.7%
Q3 24
19.4%
Q2 24
15.3%
Q1 24
8.2%
Capex Intensity
KTB
KTB
RPRX
RPRX
Q4 25
Q3 25
1.0%
Q2 25
0.5%
Q1 25
0.4%
Q4 24
1.0%
Q3 24
0.6%
Q2 24
0.6%
Q1 24
0.7%
Cash Conversion
KTB
KTB
RPRX
RPRX
Q4 25
3.86×
Q3 25
1.74×
2.44×
Q2 25
0.35×
12.06×
Q1 25
1.81×
2.50×
Q4 24
1.28×
3.57×
Q3 24
1.89×
1.29×
Q2 24
1.86×
6.45×
Q1 24
0.95×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KTB
KTB

International Member$292.0M34%
CTC Triangle B.V$192.7M23%
Lee Segment$186.7M22%
Helly Hansen Segment$185.9M22%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons